Skip to main content
SpringerLink
Log in

CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients

  • Research Article
  • Published:
Tumor Biology

Abstract

Over the years, deletions of CDKN2A (p16) tumor suppressor gene has been studied using FISH and multiplex PCR, with major focus on exon 2 in various cancers, and the frequency of mutation is found to be varied in different studies. In this study, we analyzed the deletion status of all three exons of p16 and frequency of exon 2 somatic point mutations in glioma from the Indian population and its clinical implications. Multiplex PCR was carried out in order to check deletion of all 3 exons in 50 glioma samples. Nonconventional PCR-SSCP analysis and sequencing was done to identify mutations in 48 cases. Deletion of at least one of the three exons of p16 INK4A was observed in ten cases (20 %). The frequencies of exon-wise deletions were 10 % for exon 1, 4 % for exon 2, and 8 % for exon 3. Two out of 48 samples were positive for mutations in p16 exon 2. One sample had a transition of G to C on position 147 with a codon change TGG to TGC which does not contribute to the protein structure. Another sample had a transversion of A to G on the position 154 with a codon change ATG to GTG with change in amino acid methionine to valine in 52nd position. Deletion pattern was found to be varied in three exons. Frequency of p16 gene mutation was less in the Indian population (4.2 %), and this mutation does not contribute to any remarkable change in protein structure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205(12):613–21.

    Article  CAS  PubMed  Google Scholar 

  2. Kita D, Yonekawa Y, Weller M, Ohgaki H. PI3KCA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl). 2007;113:295–302.

    Article  CAS  Google Scholar 

  3. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217–24.

    Article  CAS  PubMed  Google Scholar 

  4. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994;8(1):23–6.

    Article  CAS  PubMed  Google Scholar 

  5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753–6.

    Article  CAS  PubMed  Google Scholar 

  6. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92(6):713–23.

    Article  CAS  PubMed  Google Scholar 

  7. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000.

    Article  CAS  PubMed  Google Scholar 

  8. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosom Cancer. 1996;15(2):77–88.

    Article  CAS  PubMed  Google Scholar 

  9. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, et al. Mutations of the p16 gene in gliomas. Oncogene. 1996;12(1):63–7.

    CAS  PubMed  Google Scholar 

  10. Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene. 1995;11(3):597–600.

    CAS  PubMed  Google Scholar 

  11. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994;54(24):6353–8.

    CAS  PubMed  Google Scholar 

  12. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer. 1997;75(1):2–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M. MTS1/p16/CDKN2 lesions in primary glioblastomamultiforme. Am J Pathol. 1995;146(3):613–9.

    CAS  PubMed  Google Scholar 

  14. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 1997;94:303–9.

    Article  CAS  PubMed  Google Scholar 

  15. Barker FG, Chen P, Furman F, Aldape KD, Edwards MS, Israel MA. P16 deletion and mutation analysis in human brain tumors. J Neurooncol. 1997;31:17–23.

    Article  CAS  PubMed  Google Scholar 

  16. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. JNeurooncol. 1999;41(3):205–11.

    Article  CAS  Google Scholar 

  17. Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Mol Med. 1999;4:6.

    Google Scholar 

  18. Hamzeiy H. Non-radioactive single-strand conformation polymorphis (SSCP) analysis of relatively long PCR products. RPS. 2006;1:8–14.

    Google Scholar 

  19. Brant J. Bassam, Gustavo Caetano-Anollés, Silver staining of DNA in polyacrylamide gels. Appl Biochem Biotechnol. 1993;42(2–3):181–8.

    Google Scholar 

  20. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 1995;55(21):4818–23.

    CAS  PubMed  Google Scholar 

  21. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725–34.

    Article  CAS  PubMed  Google Scholar 

  22. Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, et al. Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol. 1997;56:999–1008.

    Article  CAS  PubMed  Google Scholar 

  23. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:984–8.

    CAS  PubMed  Google Scholar 

  24. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res. 1994;54:6338–9.

    CAS  PubMed  Google Scholar 

  25. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res. 1995;55:20–3.

    CAS  PubMed  Google Scholar 

  26. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 1996;56:150–3.

    CAS  PubMed  Google Scholar 

  27. Mochizuki S, Iwadate Y, Namba H, Yoshida Y, Yamaura A, Sakiyama S, et al. Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients. Int J Oncol. 1999;15:983–9.

    CAS  PubMed  Google Scholar 

  28. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol. 1996;55:1026–31.

    Article  CAS  PubMed  Google Scholar 

  29. Sonoda Y, Yoshimoto T, Sekiya T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene. 1995;11:2145–9.

    CAS  PubMed  Google Scholar 

  30. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer. 1996;78:287–93.

    Article  CAS  PubMed  Google Scholar 

  31. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, et al. Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastomamultiforme. J Neurosurg. 2002;96(5):815–22.

    Article  CAS  PubMed  Google Scholar 

  32. Purkait S, Jha P, Sharma MC, Suri V, Sharma M, Kale SS, et al. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology. 2013;33(4):405–12.

    Article  PubMed  Google Scholar 

  33. Sailasree R, Abhilash A, Sathyan KM, Nalinakumari KR, Thomas S, Kannan S. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. CancerEpidemiol Biomarkers Prev. 2008;17(2):414–20.

    Article  CAS  Google Scholar 

  34. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994;265(5170):415–7.

    Article  CAS  PubMed  Google Scholar 

  35. Kukita Y, Higasa K, Baba S, Nakamura M, Manago S, Suzuki A, et al. Single-strand conformation polymorphism. In: Cotton RGH, Edkins E, Forrest S, editors. Mutation detection, a practical approach. Oxford: IRL Press; 1998. p. 2259–66.

    Google Scholar 

Download references

Acknowledgments

Mr. Sibin M. K. is a CSIR-Junior research fellow, thus financial support provided by CSIR, New Delhi is kindly acknowledged.

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Human Genetics, National Institute of Mental Health and Neuro Sciences, Bangalore, 560029, India

    M. K. Sibin, Ch Lavanya, M. Jeru Manoj, S. Aakershita & G. K. Chetan

  2. Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bangalore, 560029, India

    Dhananjaya I. Bhat

Authors
  1. M. K. Sibin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dhananjaya I. Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ch Lavanya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Jeru Manoj
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Aakershita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. K. Chetan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. K. Chetan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sibin, M.K., Bhat, D.I., Lavanya, C. et al. CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients. Tumor Biol. 35, 1467–1472 (2014). https://doi.org/10.1007/s13277-013-1201-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1201-5

Keywords

Search

Navigation